Ethiopia has confirmed a deadly outbreak of Marburg virus in southern regions, according to reports from the Africa Centres for Disease Control and Prevention (Africa CDC). The highly infectious pathogen, similar to Ebola, causes severe symptoms including bleeding, fever, vomiting, and diarrhea, with an incubation period of 21 days.
Transmission of the virus occurs through contact with infected bodily fluids. Unfortunately, the fatality rate stands at a staggering 25-80%, making it one of the most deadly known pathogens.
A recent confirmation by Ethiopia's Tedros Adhanom Ghebreyesus comes two days after Africa CDC alerted to a suspected haemorrhagic fever in southern regions. The National Reference Laboratory has since identified Marburg virus disease, prompting swift action from Ethiopian health authorities to contain the outbreak.
Investigations are currently underway to further understand the strain of the virus detected in Jinka area, with similarities observed to previously identified cases in east Africa. Rwanda's experience with a Marburg epidemic in December 2024 is mentioned as an example of successful containment.
However, Ethiopia and global health authorities are facing the challenge of addressing the outbreak without an approved vaccine or antiviral treatment for the virus. In such cases, administering oral or intravenous rehydration, along with targeted symptom treatment, significantly increases patients' chances of survival.
Rwanda recently conducted trials on an experimental Marburg vaccine, a promising development in the fight against this deadly pathogen.
Transmission of the virus occurs through contact with infected bodily fluids. Unfortunately, the fatality rate stands at a staggering 25-80%, making it one of the most deadly known pathogens.
A recent confirmation by Ethiopia's Tedros Adhanom Ghebreyesus comes two days after Africa CDC alerted to a suspected haemorrhagic fever in southern regions. The National Reference Laboratory has since identified Marburg virus disease, prompting swift action from Ethiopian health authorities to contain the outbreak.
Investigations are currently underway to further understand the strain of the virus detected in Jinka area, with similarities observed to previously identified cases in east Africa. Rwanda's experience with a Marburg epidemic in December 2024 is mentioned as an example of successful containment.
However, Ethiopia and global health authorities are facing the challenge of addressing the outbreak without an approved vaccine or antiviral treatment for the virus. In such cases, administering oral or intravenous rehydration, along with targeted symptom treatment, significantly increases patients' chances of survival.
Rwanda recently conducted trials on an experimental Marburg vaccine, a promising development in the fight against this deadly pathogen.